市場調査レポート

商品コード

1576086

脂質低下薬の世界市場の評価：タイプ別、薬剤クラス別、適応症別、投与経路別、流通チャネル別、地域別、機会、予測（2017年～2031年）

Lipid-lowering Drugs Market Assessment, By Type, By Drug Class, By Indication, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年10月24日
発行: Market Xcel - Markets and Data
ページ情報: 英文 236 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 646,065円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 818,349円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,177,274円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の脂質低下薬の市場規模は、2023年の303億米ドルから2031年に384億7,000万米ドルに達すると予測され、2024年～2031年の予測期間にCAGRで3.03％の成長が見込まれます。市場は、心疾患の有病率の増加、早期診断と適切な治療レジメンの重視の高まりに加え、医療ステークホルダーの心臓の健康に対する関心とこの分野への投資、規制政策の改善により、より速いペースで拡大すると予測されます。

脂質低下薬は、血中のコレステロールとトリグリセリドを低下させ、心血管疾患を予防し、脂質障害を管理するのに役立ちます。脂質異常症治療薬または抗脂質異常症薬としても知られています。座りがちな生活習慣、不健康な食べ物の選択、ストレスによって引き起こされる心血管疾患の有病率の増加が、このような薬剤の主な市場需要となっています。市場拡大の主なハードルは、従来の薬剤の普及と新治療オプションの採用率のミスマッチによる緊張です。しかし、新薬の規制当局による承認は新たな市場機会を提供し、市場の成長を可能にすると予測されます。2024年3月、Esperion Therapeutics, Inc.は、同社の脂質低下薬であるNEXLETOL（ベムペド酸）とNEXLIZET（ベムペド酸、エゼチミブ）の適応拡大がUSFDAによって承認されたと発表しました。これらの承認は、スタチンの使用にかかわらず、一次予防および二次予防の患者への心血管リスク軽減に向けた使用を認めるものです。これにより、対象となる患者集団が約7,000万人に拡大し、非スタチン系LDL-C低下療法が大きく前進することになります。

当レポートでは、世界の脂質低下薬市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

市場規模の分析と予測
- 金額
市場シェアの分析と予測
- タイプ別
- 薬剤クラス別
- 適応症別
- 投与経路別
- 流通チャネル別
- 地域別
- 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
市場マップ分析（2023年）
- タイプ別
- 薬剤クラス別
- 適応症別
- 投与経路別
- 流通チャネル別
- 地域別

第5章北米の脂質低下薬市場の見通し（2017年～2031年）

市場規模の分析と予測
- 金額
市場シェアの分析と予測
- タイプ別
- 薬剤クラス別
- 適応症別
- 投与経路別
- 流通チャネル別
- シェア：国別
各国の市場の評価
- 米国の脂質低下薬市場の見通し（2017年～2031年）
- カナダ
- メキシコ

第6章欧州の脂質低下薬市場の見通し（2017年～2031年）

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
ポーランド

第7章アジア太平洋の脂質低下薬市場の見通し（2017年～2031年）

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第8章南米の脂質低下薬市場の見通し（2017年～2031年）

ブラジル
アルゼンチン

第9章中東・アフリカの脂質低下薬市場の見通し（2017年～2031年）

サウジアラビア
アラブ首長国連邦
南アフリカ
イスラエル

第10章需給分析

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第13章 PESTLE分析

第14章価格分析

第15章市場力学

市場促進要因
市場の課題

第16章市場の動向と発展

第17章規制枠組みとイノベーション

臨床試験
規制当局の承認

第18章特許情勢

第19章ケーススタディ

第20章競合情勢

マーケットリーダー上位5社の競合マトリクス
上位5社のSWOT分析
主要企業上位10社の情勢
- Amgen Inc.
- Novartis AG
- Dr. Reddy's Laboratories Limited
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.

第21章戦略的推奨

第22章当社について、免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 3. Global Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 4. Global Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 5. Global Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 6. Global Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 7. Global Lipid-lowering Drugs Market Share (%), By Region, 2017-2031F
Figure 8. North America Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 9. North America Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 10. North America Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 11. North America Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 12. North America Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 13. North America Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 14. North America Lipid-lowering Drugs Market Share (%), By Country, 2017-2031F
Figure 15. United States Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 16. United States Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 17. United States Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 18. United States Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 19. United States Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 20. United States Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 21. Canada Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 22. Canada Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 23. Canada Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 24. Canada Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 25. Canada Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 26. Canada Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 27. Mexico Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 28. Mexico Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 29. Mexico Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 30. Mexico Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 31. Mexico Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 32. Mexico Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 33. Europe Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 34. Europe Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 35. Europe Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 36. Europe Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 37. Europe Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 38. Europe Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 39. Europe Lipid-lowering Drugs Market Share (%), By Country, 2017-2031F
Figure 40. Germany Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 41. Germany Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 42. Germany Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 43. Germany Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 44. Germany Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 45. Germany Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 46. France Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 47. France Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 48. France Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 49. France Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 50. France Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 51. France Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 52. Italy Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 53. Italy Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 54. Italy Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 55. Italy Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 56. Italy Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 57. Italy Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 58. United Kingdom Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 59. United Kingdom Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 60. United Kingdom Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 61. United Kingdom Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 62. United Kingdom Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 63. United Kingdom Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 64. Russia Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 65. Russia Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 66. Russia Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 67. Russia Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 68. Russia Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 69. Russia Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 70. Netherlands Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 71. Netherlands Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 72. Netherlands Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 73. Netherlands Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 74. Netherlands Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 75. Netherlands Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 76. Spain Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 77. Spain Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 78. Spain Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 79. Spain Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 80. Spain Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 81. Spain Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 82. Turkey Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 83. Turkey Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 84. Turkey Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 85. Turkey Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 86. Turkey Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 87. Turkey Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 88. Poland Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 89. Poland Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 90. Poland Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 91. Poland Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 92. Poland Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 93. Poland Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 94. South America Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 95. South America Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 96. South America Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 97. South America Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 98. South America Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 99. South America Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 100. South America Lipid-lowering Drugs Market Share (%), By Country, 2017-2031F
Figure 101. Brazil Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 102. Brazil Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 103. Brazil Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 104. Brazil Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 105. Brazil Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 106. Brazil Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 107. Argentina Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 108. Argentina Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 109. Argentina Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 110. Argentina Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 111. Argentina Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 112. Argentina Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 113. Asia-Pacific Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 114. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 115. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 116. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 117. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 118. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 119. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Country, 2017-2031F
Figure 120. India Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 121. India Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 122. India Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 123. India Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 124. India Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 125. India Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 126. China Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 127. China Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 128. China Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 129. China Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 130. China Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 131. China Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 132. Japan Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 133. Japan Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 134. Japan Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 135. Japan Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 136. Japan Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 137. Japan Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 138. Australia Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 139. Australia Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 140. Australia Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 141. Australia Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 142. Australia Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 143. Australia Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 144. Vietnam Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 145. Vietnam Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 146. Vietnam Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 147. Vietnam Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 148. Vietnam Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 149. Vietnam Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 150. South Korea Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 151. South Korea Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 152. South Korea Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 153. South Korea Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 154. South Korea Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 155. South Korea Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 156. Indonesia Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 157. Indonesia Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 158. Indonesia Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 159. Indonesia Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 160. Indonesia Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 161. Indonesia Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 162. Philippines Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 163. Philippines Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 164. Philippines Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 165. Philippines Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 166. Philippines Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 167. Philippines Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 168. Middle East & Africa Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 169. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 170. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 171. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 172. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 173. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 174. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Country, 2017-2031F
Figure 175. Saudi Arabia Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 176. Saudi Arabia Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 177. Saudi Arabia Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 178. Saudi Arabia Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 179. Saudi Arabia Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 180. Saudi Arabia Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 181. UAE Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 182. UAE Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 183. UAE Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 184. UAE Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 185. UAE Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 186. UAE Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 187. South Africa Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
Figure 188. South Africa Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
Figure 189. South Africa Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
Figure 190. South Africa Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
Figure 191. South Africa Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
Figure 192. South Africa Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX12133

Global lipid-lowering drugs market is projected to witness a CAGR of 3.03% during the forecast period 2024-2031, growing from USD 30.30 billion in 2023 to USD 38.47 billion in 2031. The market of lipid-lowering drugs is anticipated to expand at a faster pace owing to the rising prevalence of cardiac diseases, the growing emphasis on early diagnosis, and proper treatment regimens, coupled with healthcare stakeholders' attention towards heart health through investment in the field, and improved regulatory policies.

Lipid-lowering drugs help lower cholesterol and triglycerides in the blood, prevent cardiovascular diseases, and manage lipid disorders. They are also known as hyperlipidemia drugs or antihyperlipidemic drugs. The rising prevalence of cardiovascular diseases caused by sedentary lifestyles, unhealthy food choices, and stress is the primary market demand for such drugs. The primary hurdle for the expansion of this market is the tension between the widespread utilization of conventional drugs and novel treatment options owing to a mismatch in the adoption rate. However, the new drugs' regulatory approvals are expected to offer new market opportunities and enable market growth. In March 2024, Esperion Therapeutics, Inc. announced that the USFDA approved expanded labels for its lipid-lowering drugs, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe). These approvals allow their use for cardiovascular risk reduction in primary and secondary prevention patients, regardless of statin use. It broadens the eligible patient population to approximately 70 million, significantly advancing in non-statin LDL-C lowering therapies.

High Cardiovascular Disease Burden to Boost Demand for Lipid-lowering Drugs

High lipid levels, especially high LDL cholesterol and triglycerides, trigger the development of cardiovascular diseases by promoting atherosclerosis. Hailed by increasing cases of cardiac diseases from lifestyles such as diet, sedentary lifestyle, and obesity, the need for lipid-lowering medications is profoundly greater than ever. Increasing prescriptions for statins and other lipid-modifying therapies to manage cholesterol and attenuate cardiovascular risk is expected to accelerate growth in the market for lipid-lowering drugs. Improvements in treatment options and personalized medicine further drive the ever-growing trend as healthcare providers seek more effective alternatives to combat the growing epidemic of rising lipid levels. For instance, according to an article published in Circulation Journal in June 2024, the prevalence of hypertension is projected to increase from 51.2% in 2020 to 61.0% in 2050. It is estimated that the prevalence of poor diet, inadequate physical activity, and smoking will improve over time, while inadequate sleep will worsen. Additionally, the prevalence of coronary disease, heart failure, stroke, atrial fibrillation, and total cardiovascular disease are expected to increase. Clinical cardiovascular diseases (CVD) are projected to affect 45 million adults, and CVD, including hypertension, will affect more than 184 million adults by 2050, which is more than 61% of the population.

Robust Drug Development Pipeline to Drive Market Growth

A strong drug development pipeline is one of the growth drivers in the market for lipid-lowering drugs. New research and results of clinical trials have led to the arrival of novel therapies answering different types of patient needs, such as genetic lipid disorders and intolerance to traditional statin therapy. Emerging classes of drugs, including PCSK9 inhibitors and other novel agents, provide efficient treatment alternatives. Personalization gets its stronghold in the ready availability of bespoke therapies, supported through genetic profiles, improving patient outcomes and compliance. The greater focus on preventive health care further helps add to the demand for effective solutions to manage lipids, ensuring a strong pipeline converts into significant market growth. For instance, in April 2024, Verve Therapeutics, Inc. announced updates on its PCSK9 program, highlighting the Heart-1 clinical trial of VERVE-101, which showed LDL-C reductions of up to 73%. However, the enrollment was paused due to safety concerns related to a participant. The company will prioritize VERVE-102, which uses a different delivery system and is set to enter the Heart-2 trial in Q2 2024, focusing on lipid-lowering treatments.

Statins and Combinations to Dominate the Lipid-lowering Drugs Market Share

The segment of statins and combinations holds the largest share of the lipid-lowering drugs market as they are proven to be effective and widely used, besides having significant clinical support. Atorvastatin and rosuvastatin are examples of effective statins that decrease the levels of LDL cholesterol and mean a substantial reduction in cardiovascular events. They have a long-proven record and are firmly embedded in preventive medicine. Also, the economic nature of generic statins supports their usability among healthcare providers and patients, enabling access to treatment for a larger population. Moreover, in the context of developing recognition of benefits beyond lipid-lowering, research is still ongoing on the anti-inflammatory properties of statins, making them more appealing. Therefore, with continuous improvement of the formulation and dosage of formulations, the segment of statins remains the core of lipid management by ensuring its dominance in the market for the foreseeable future. As per an article published in August 2024 in the Canadian Journal of Cardiology and several other literary sources, statins are proven to lower LDL-C levels ranging from 20%-60%, positioning them to be highly effective in the lipid-lowering drug category.

North America to Dominate the Lipid-lowering Drugs Market Share

The presence of several key factors, such as the high prevalence of cardiovascular diseases and obesity, leading North America to dominate the market for lipid-lowering drugs. The healthcare infrastructure is well established, with easy access to medical services that ensure timely diagnosis and treatment of hyperlipidemia. There is increased awareness of cardiovascular health among the population, leading to proactive screening and adherence to prescribed therapies. Major pharmaceutical companies in North America are fueling innovation by introducing new lipid-lowering medications. Additional factors favorable to the patient on lipid-lowering drugs are policies and insurance coverage for reimbursement. The regulatory initiatives from the USFDA further strengthen the market growth rate in the region. For instance, in March 2024, Regeneron Pharmaceuticals, Inc. announced that the USFDA extended the approval of Praluent (alirocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies to include pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH).

Future Market Scenario (2024 - 2031F)

Recent advancements in the development of lipid-lowering drugs are changing the face of the cardiovascular market. Among these, emerging therapies targeting multiple pathways beyond the usual statins meet major needs in managing dyslipidemia. New molecules, like bempedoic acid and inclisiran, represent novel approaches. Bempedoic acid selectively inhibits cholesterol synthesis in the liver and makes it unable to synthesize cholesterol. In contrast, inclisiran is a siRNA that drastically lowers levels of LDL-C at very infrequent dosing. In addition, drugs targeting ANGPTL3 and ApoC-III for reduction in triglycerides and lipoprotein(a) may further change the management of patients resistant to treatments in use. All these developments are bound to impact market growth as they expand the array of treatments that are being put at the disposal of patients with a high cardiovascular risk profile. The new agents enhance the management of lipids and indicate atherosclerotic event reduction, therefore improving patient compliance and demand on the market.

Key Players Landscape and Outlook

The market players involved in manufacturing lipid-lowering drugs range from local generic drug producers to global pharmaceutical giants fragmenting the market. However, there are many market players, branded drugs, such as Repatha from Amgen Inc., attract a significant market share in terms of revenue. Recent activities in the market include regulatory initiatives, manufacturing collaborations, and acquisitions.

In October 2024, AstraZeneca announced an exclusive license agreement with CSPC Pharmaceutical Group Ltd to fasten the development of YS2302018, a novel lipid-lowering asset targeting lipoprotein(a) CSPC. This collaboration aims to develop therapies that can significantly reduce cardiovascular disease risk associated with elevated lipoprotein(a) levels. The agreement underscores AstraZeneca's commitment to advancing innovative treatments in cardiovascular health, potentially enhancing its portfolio in lipid management.

In May 2024, Click Therapeutics, Inc. announced its expansion into obesity and cardiometabolic diseases through the acquisition of Better Therapeutics, Inc.'s assets, including the FDA-authorized AspyreRx for type 2 diabetes, and the development of candidates, such as BT-002, BT-003, and BT-004, for hyperlipidemia and metabolic dysfunction-associated steatohepatitis (MASH). The focus will be on developing AspyreRx for obesity treatment and optimizing it alongside anti-obesity medications. This initiative aims to enhance patient outcomes and leverage AI-enabled platforms for personalized care in chronic weight management and related conditions.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Lipid-lowering Drugs Market Outlook, 2017-2031F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Type
  - 4.2.1.1. Branded
  - 4.2.1.2. Generic
- 4.2.2. By Drug Class
  - 4.2.2.1. Statins and Combinations
  - 4.2.2.2. Bile Acid Sequestrants
  - 4.2.2.3. Cholesterol Absorption Inhibitors
  - 4.2.2.4. Fibric Acid Derivatives
  - 4.2.2.5. PCSK9 Inhibitors
  - 4.2.2.6. Other Drug Classes
- 4.2.3. By Indication
  - 4.2.3.1. Hypercholesterolemia
  - 4.2.3.2. Coronary Artery Disease
  - 4.2.3.3. High Triglycerides
- 4.2.4. By Route of Administration
  - 4.2.4.1. Oral
  - 4.2.4.2. Parenteral
- 4.2.5. By Distribution Channel
  - 4.2.5.1. Hospital Pharmacies
  - 4.2.5.2. Retail Pharmacies
  - 4.2.5.3. Online Pharmacies
  - 4.2.5.4. Others
- 4.2.6. By Region
  - 4.2.6.1. North America
  - 4.2.6.2. Europe
  - 4.2.6.3. Asia-Pacific
  - 4.2.6.4. South America
  - 4.2.6.5. Middle East and Africa
- 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
4.3. Market Map Analysis, 2023
- 4.3.1. By Type
- 4.3.2. By Drug Class
- 4.3.3. By Indication
- 4.3.4. By Route of Administration
- 4.3.5. By Distribution Channel
- 4.3.6. By Region

5. North America Lipid-lowering Drugs Market Outlook, 2017-2031F*

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Type
  - 5.2.1.1. Branded
  - 5.2.1.2. Generic
- 5.2.2. By Drug Class
  - 5.2.2.1. Statins and Combinations
  - 5.2.2.2. Bile Acid Sequestrants
  - 5.2.2.3. Cholesterol Absorption Inhibitors
  - 5.2.2.4. Fibric Acid Derivatives
  - 5.2.2.5. PCSK9 Inhibitors
  - 5.2.2.6. Other Drug Classes
- 5.2.3. By Indication
  - 5.2.3.1. Hypercholesterolemia
  - 5.2.3.2. Coronary Artery Disease
  - 5.2.3.3. High Triglycerides
- 5.2.4. By Route of Administration
  - 5.2.4.1. Oral
  - 5.2.4.2. Parenteral
- 5.2.5. By Distribution Channel
  - 5.2.5.1. Hospital Pharmacies
  - 5.2.5.2. Retail Pharmacies
  - 5.2.5.3. Online Pharmacies
  - 5.2.5.4. Others
- 5.2.6. By Country Share
  - 5.2.6.1. United States
  - 5.2.6.2. Canada
  - 5.2.6.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Lipid-lowering Drugs Market Outlook, 2017-2031F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Type
      - 5.3.1.2.1.1. Branded
      - 5.3.1.2.1.2. Generic
    - 5.3.1.2.2. By Drug Class
      - 5.3.1.2.2.1. Statins and Combinations
      - 5.3.1.2.2.2. Bile Acid Sequestrants
      - 5.3.1.2.2.3. Cholesterol Absorption Inhibitors
      - 5.3.1.2.2.4. Fibric Acid Derivatives
      - 5.3.1.2.2.5. PCSK9 Inhibitors
      - 5.3.1.2.2.6. Other Drug Classes
    - 5.3.1.2.3. By Indication
      - 5.3.1.2.3.1. Hypercholesterolemia
      - 5.3.1.2.3.2. Coronary Artery Disease
      - 5.3.1.2.3.3. High Triglycerides
    - 5.3.1.2.4. By Route of Administration
      - 5.3.1.2.4.1. Oral
      - 5.3.1.2.4.2. Parenteral
    - 5.3.1.2.5. By Distribution Channel
      - 5.3.1.2.5.1. Hospital Pharmacies
      - 5.3.1.2.5.2. Retail Pharmacies
      - 5.3.1.2.5.3. Online Pharmacies
      - 5.3.1.2.5.4. Others
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Lipid-lowering Drugs Market Outlook, 2017-2031F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland

7. Asia-Pacific Lipid-lowering Drugs Market Outlook, 2017-2031F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Lipid-lowering Drugs Market Outlook, 2017-2031F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Lipid-lowering Drugs Market Outlook, 2017-2031F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

15.1. Market Drivers
15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

17.1. Clinical Trials
17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

20.1. Competition Matrix of Top 5 Market Leaders
20.2. SWOT Analysis for Top 5 Players
20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. Amgen Inc.
  - 20.3.1.1. Company Details
  - 20.3.1.2. Key Management Personnel
  - 20.3.1.3. Products and Services
  - 20.3.1.4. Financials (As Reported)
  - 20.3.1.5. Key Market Focus and Geographical Presence
  - 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 20.3.2. Novartis AG
- 20.3.3. Dr. Reddy's Laboratories Limited
- 20.3.4. GlaxoSmithKline plc
- 20.3.5. Merck & Co., Inc.
- 20.3.6. Pfizer Inc.
- 20.3.7. Regeneron Pharmaceuticals, Inc.
- 20.3.8. Teva Pharmaceuticals Industries Ltd.
- 20.3.9. Sanofi S.A.
- 20.3.10. Sun Pharmaceutical Industries Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

脂質低下薬の世界市場の評価：タイプ別、薬剤クラス別、適応症別、投与経路別、流通チャネル別、地域別、機会、予測（2017年～2031年）

Lipid-lowering Drugs Market Assessment, By Type, By Drug Class, By Indication, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の脂質低下薬市場の見通し（2017年～2031年）

第5章 北米の脂質低下薬市場の見通し（2017年～2031年）

第6章 欧州の脂質低下薬市場の見通し（2017年～2031年）

第7章 アジア太平洋の脂質低下薬市場の見通し（2017年～2031年）

第8章 南米の脂質低下薬市場の見通し（2017年～2031年）

第9章 中東・アフリカの脂質低下薬市場の見通し（2017年～2031年）

第10章 需給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析